None
Quote | CSPC Pharmaceutical Group Ltd ADR (OTCMKTS:CSPCY)
Last: | $3.02 |
---|---|
Change Percent: | -0.57% |
Open: | $3.0371 |
Close: | $3.02 |
High: | $3.0371 |
Low: | $3.018 |
Volume: | 6,197 |
Last Trade Date Time: | 07/17/2024 03:00:00 am |
News | CSPC Pharmaceutical Group Ltd ADR (OTCMKTS:CSPCY)
2024-07-12 08:41:47 ET More on CSPC Pharmaceutical, Moderna, etc. Moderna: Really Strong Competition Moment Of Truth Approaches For Moderna's RSV Vaccine Moderna, Inc. (MRNA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Moderna, Mitsubi...
2024-01-29 09:00:03 ET More on Corbus Pharmaceuticals Corbus Pharma surges after early Phase 1 data for tumor candidate Seeking Alpha’s Quant Rating on Corbus Pharmaceuticals Historical earnings data for Corbus Pharmaceuticals Financial information for...
Message Board Posts | CSPC Pharmaceutical Group Ltd ADR (OTCMKTS:CSPCY)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
CSPC Pharmaceutical Group Ltd ADR Company Name:
CSPCY Stock Symbol:
OTCMKTS Market:
Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023 PR Newswire Initial data showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refract...
Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023 PR Newswire NEW YORK , April 26, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology comp...
Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC) PR Newswire CRB-701 (SYS6002) is designed for improved therapeutic index and to act on a broad range of Nectin-4 expressing tumors ...